March 22, 2017
New evergreen fund to help Ontario discoveries reach seed-stage funding faster
TORONTO, March 21, 2017 /CNW/ – Fight Against Cancer Innovation Trust (“FACIT”) is pleased to announce the launch of The Prospects Oncology Fund (“Prospects Fund”), designed to advance early-stage Ontario cancer discoveries by supporting the proof-of-concept studies needed to attract seed-stage investment. Managed by FACIT, this is an evergreen fund to which capital is allocated annually.
March 22, 2017
Seed financing of CAD$3.0M positions first-in-class WDR5 cancer therapy for clinical development
TORONTO, March 22, 2017 /CNW/ – FACIT announced a seed stage investment in Propellon Therapeutics (the “Company” or “Propellon”), a start-up created by FACIT focused on developing a portfolio of WDR5-targeted anti-cancer therapeutics. FACIT’s investment, combined with non-dilutive capital, achieves a targeted $3.0M financing for the lead program. The seed funding enables Propellon to accelerate the nomination of a candidate drug and position the Company for financing and/or entering a strategic partnership for clinical trials in patients with haematological cancers.
March 9, 2017
New molecular barcode technology reduces error rate in genomic sequencing to 1 in 10,000
Toronto (March 9, 2017) – Researchers at the Ontario Institute for Cancer Research (OICR), together with international collaborators, have invented a technique to avoid a major problem with common laboratory techniques and improve the sensitivity of important cancer tests.
February 23, 2017
Digital Detection Tool Will Be Shared Freely Over the Web
Toronto, ON and Baltimore, MD (February 23, 2017) A research team from the United States and Canada has developed and successfully tested new computational software that determines whether a human DNA sample includes an epigenetic add-on linked to cancer and other adverse health conditions.
February 23, 2017
Financing leverages and strengthens Ontario’s next-generation radiotherapeutics expertise, products
TORONTO, ON (February 23, 2017) – The Fight Against Cancer Innovation Trust (FACIT) and the Ontario Institute for Cancer Research (OICR) are pleased to report that Fusion Pharmaceuticals Inc. (Fusion) has closed a US$25M Series A financing, with Johnson & Johnson Innovation – JJDC, Inc. (JJDC) as the lead investor. Additional, new investors include venture groups HealthCap, TPG Biotechnology Partners, and Genesys Capital, as well as founding investor FACIT.
February 10, 2017
OICR researchers to be part of Cancer Research UK’s Grand Challenge helping to answer cancer’s biggest questions
Toronto (February 10, 2017) – Ontario Institute for Cancer Research (OICR) researchers Drs. Lincoln Stein and Steven Gallinger have been announced as members of one of the first global research teams to be recipients of Cancer Research UK’s Grand Challenge.
The Grand Challenge aims to help overcome the biggest challenges facing cancer research in a global effort to beat cancer sooner.
Stein and Gallinger’s pioneering team will study samples from five continents to understand the DNA damage associated with different cancers, to understand what causes them and if they can be prevented. The project will be led by Professor Mike Stratton at the Wellcome Trust Sanger Institute, Cambridge, with collaborators from France, the U.S. and U.K.
Tags: Media release
January 9, 2017
Findings published in renowned journal Nature
January 9, 2017 – TORONTO, ON – The Canadian Prostate Cancer Genome Network (CPC-GENE) has published findings from the world’s most comprehensive genetic analysis of prostate cancer tumours in the journal Nature. Led by Drs. Robert Bristow of the Princess Margaret Cancer Centre and Paul Boutros of the Ontario Institute for Cancer Research, CPC-GENE has uncovered the full set of mutations that can occur in the most common cancer in men. By fully cataloging these mutations, the CPC-GENE team was able to create a new signature that predicts at an early stage whether a prostate cancer tumour will become aggressive or not, allowing for personalized treatment.
November 2, 2016
OrbiMed, Versant-led round continues commercialization success for Turnstone’s cancer therapies
TORONTO, Nov. 2, 2016 /CNW/ – Turnstone Biologics Inc. (“Turnstone”), an Ontario-based developer of novel oncolytic viral immunotherapies, announced the closing of a USD $41.4 million Series B financing led by OrbiMed Advisors LLC (“OrbiMed”) and Versant Ventures (“Versant”), which led Turnstone’s Series A round in October 2015. New investor F-Prime Capital Partners (“F-Prime”) and existing founding investor FACIT also participated. Proceeds from the financing will support an ongoing Phase I/II clinical trial in patients with advanced or metastatic solid tumours as well as accelerate and expand Turnstone’s pipeline, funding the development of three additional programs into the clinic. In connection with the financing Orbimed’s Rishi Gupta, JD and F-Prime’s Ben Auspitz will join Turnstone’s board of directors alongside Versant’s Brad Bolzon, PhD and Jerel Davis, PhD as well as FACIT’s Jeff Courtney.
October 12, 2016
The findings provide important insights into how pancreas cancer develops and spreads and new strategies for better understanding one of the mostly deadly types of cancer.
Toronto (October 12, 2016) – Researchers in the multidisciplinary PanCuRx research initiative at the Ontario Institute for Cancer Research (OICR) and University Health Network’s Princess Margaret Cancer Centre, led by Dr. Faiyaz Notta and Dr. Steven Gallinger, today published new findings that challenge current beliefs about how and why pancreas cancer is so aggressive.
October 6, 2016
The data are being shared with the wider biological research community to help in the development of new therapies for diseases like cancer.
Toronto (October 6, 2016) – The European Bioinformatics Institute (EMBL-EBI), the New York University School of Medicine and the Ontario Institute for Cancer Research (OICR) today announced a major milestone in the Reactome project: the annotation and release of its 10,000th human protein, making it the most comprehensive open access pathway knowledgebase available to the scientific community.
August 17, 2016
Toronto (August 17, 2016) – Mr. Peter Goodhand, President of The Ontario Institute for Cancer Research (OICR), today announced a new collaborative research study in partnership with Thermo Fisher Scientific and Queen’s University to help bring more targeted diagnosis and treatment to breast cancer patients in the future.
Tags: Media release
July 14, 2016
An open challenge that merges the efforts of the International Cancer Genome Consortium, The Cancer Genome Atlas, and the NCI Cloud Pilots with Sage Bionetworks and the open science DREAM Challenge community
For more information on OICR's research, careers, events and education, visit our corporate website: OICR.ON.CA